A Structured Approach to Managing Pregnancy in Individuals with Inflammatory Arthritis

Overview

Inflammatory arthritis (IA) disproportionately affects women, impacting family planning decisions due to concerns about disease activity, medication safety, and pregnancy outcomes. This report presents a comprehensive clinical care pathway to guide healthcare providers in managing pregnancy in patients with IA, emphasizing preconception counseling, contraception, and multidisciplinary care.

Background

Inflammatory arthritides, including rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis, affect a significant portion of the Canadian population, with women being three times more likely to be affected than men. The predominance of IA in women influences reproductive health and family planning. Many women with IA experience anxiety regarding pregnancy risks, disease management during pregnancy, and medication safety for their infants. Existing international guidelines provide recommendations, but there is a lack of Canadian-specific resources to support shared decision-making in clinical practice.

Data Highlights

A survey of 439 Canadian women with inflammatory arthritis revealed that only 46% received preconception counseling from their rheumatologists regarding pregnancy risks and medication safety. Rheumatoid arthritis affects approximately 1.2% of the Canadian population, equating to about 375,000 individuals. Long-acting reversible contraceptives have a failure rate of less than 1% per year, making them the preferred contraception method for women with IA.

Key Findings

• Only 46% of women with IA receive preconception counseling from rheumatologists, indicating a gap in reproductive health communication.
• Reliable contraception is underutilized among women with IA, despite its importance in preventing unplanned pregnancies and associated risks.
• Long-acting reversible contraceptives (IUDs and subdermal implants) are recommended as first-line contraception due to their safety and efficacy.
• Contraceptive choices should consider clinical factors such as drug interactions, comorbidities, and antiphospholipid antibody status.
• Emergency hormonal contraceptives are safe and available over-the-counter for women with IA.
• Genetic heritability of IA exists but the overall prevalence in the general population remains low, which is important for counseling patients about offspring risk.

Clinical Implications

Healthcare providers should proactively address reproductive health and family planning with women who have inflammatory arthritis, incorporating preconception counseling into routine care. Emphasizing the use of effective contraception until disease control is achieved on pregnancy-compatible medications can reduce pregnancy-related risks. Multidisciplinary collaboration among rheumatologists, obstetricians, and allied health professionals is essential to support informed decision-making and optimize maternal and infant outcomes.

Conclusion

A structured, evidence-based clinical care pathway tailored to women with inflammatory arthritis can improve pregnancy planning and management, addressing patient concerns and enhancing shared decision-making. Implementing such guidance in Canadian practice will help bridge current gaps in care and support healthier pregnancies in this population.

References

1. Canadian Arthritis Statistics 2020 -- Arthritis Society
2. Prevalence of Rheumatoid Arthritis in Canada -- Canadian Journal of Rheumatology
3. Sex Differences in Rheumatoid Arthritis -- Rheumatology International
4. British Society of Rheumatology Guidelines 2020 -- BSR
5. American College of Rheumatology Recommendations 2021 -- ACR
6. European League Against Rheumatism Recommendations 2019 -- EULAR
7. Survey on Pregnancy Counseling in IA Patients -- Canadian Rheumatology Association